Zoomedia Blog
Blog Posts for Tag: Clinical
The talk of the town since the conclusion of this historic election has been understandably focused on on how to fix the economy, pull out of Iraq over the next 16 months, and pursue clean energy alternatives. The magnitude of tasks that President-elect Obama has to contend with are staggering and each of them demand immediate action and long-term vision. However, through the fog of campaign rhetoric and economic meltdown in the US and in Europe, very little has been said about how the United States can take a real leadership position with helping to eradicate global disease through the commercialization of affordable life- saving therapeutics and vaccines for developing countries.
Tags: Product Strategy, Investor Strategy, Clinical Trial Strategy, Non-Profits
Our clients know that the litany of negative headlines from the financial sector in the past month has not escaped the eyes and minds of marketing departments budget crunchers throughout the life sciences. In response to the economic uncertainty, many biotech and pharma companies are cutting non-core spending to maintain internal stability. Reduced budgets present the proverbial challenge that "tools are needed to build a ship." Yet marketers are charged with delivering the corporate or product message out, building sales and partnerships, and developing brand awareness. In this catch-22, how can the industry best stretch its marketing dollars?
Tags: SEM, RSS, Online Marketing, Viral Marketing, Product Strategy, Investor Strategy, Clinical Trial Strategy
Last week, I attended the Epilepsy Pipeline Update conference, provided by our client the Epilepsy Therapy Project. The Epilepsy Therapy Project exists to overcome the barriers to successful translation of promising new research insights and to make new therapies a reality for patients...
Tags: Patient Strategy, Clinical Strategy, Epilepsy Therapy Project
I am the CEO of a communications agency that depends directly on DTC and DTP advertising for a significant portion of our bottom line. One of our largest clients is a non-profit patient advocacy group. In addition, we have many, many clients who have to balance their passion for finding cures with their need to satisfy their investors' expectations. As we begin 2008 and listen to the Presidential candidates views on healthcare, we hear a lot of strident voices within industry often pitted against patient advocacy. It seems that there's a lot of talk about change, a lot of serious resistance to change, and a lot of skeptics who say the pharmaceutical industry will never change.
